T.Rx Capital Fund I, LP
Open, writing first checksEmerging manager
Open: first sale Feb 2024, per Form D (fund age approximates vintage)
- Vintage
- 2024
- Fund size
- $77.2M to $175M (Form D)
- Stages
- Seed, Series A, Series B
- Sectors
- Biotech, Healthtech
- Regions
- Global
01 · Thesis
T.Rx Capital Fund I, LP targets early-stage healthcare investments, with a focus on company creation through Series B. The firm aims to build a concentrated portfolio of 10 to 15 companies.
02 · Initial check
$772K to $2.92M (estimated from fund size)
Estimated from Form D: $77.2M sold of a $175M target
03 · Who to approach
Named on this fund's Form D
- Michael Langer, Co-founder & Managing Partner
- Kwesi Frimpong-Boateng, Co-founder & Managing Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
T.Rx Capital Fund I targets early-stage investments across healthcare, with a focus on company creation through Series B. The firm aims to build a concentrated portfolio of 10–15 companies.
T.Rx Capital Fund I targets early-stage investments across healthcare, with a focus on company creation through Series B.
https://www.trxcap.com/posts/t-rx-capital-launches-77-5m-fund-i-to-invest-in-bold-startups-at-the-intersection-of-technology-and-biology
06 · Sources
Last verified: Oct 25, 2026